Rheumatology

Back to articles

Rheumatoid arthritis: New study supports clinical benefits of DMARDs

KEY POINT

In patients with rheumatoid arthritis (RA) who were eligible for biologics, a combination of disease-modifying antirheumatic drugs (DMARDs) was noninferior to a tumor necrosis factor (TNF) inhibitor in terms of clinical benefit.